Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CTAD 2024 | The value and limitations of p-tau217 in AD clinical trials

Todd Feaster • 29 Oct 2024
CTAD 2024
Alzheimer’s Disease Dementia

Todd Feaster, PsyD, Acumen Pharmaceuticals, Carmel, IN, comments on the value of p-tau217 biomarkers in Alzheimer’s disease (AD) clinical trials, highlighting their ability to improve participant selection, reduce unnecessary burdens on study participants, and save time and resources. Dr Feaster notes that this assay does not carry a CE mark, restricting its use in European cohorts. This interview took place at the 17th Clinical Trials on Alzheimer’s Disease (CTAD) congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Todd Feaster

Using a p-tau217 assay to screen participants for the ALTITUDE-AD trial 2:13
Using a p-tau217 assay to screen participants for the ALTITUDE-AD trial
Todd Feaster • 29 Oct 2024
The ALTITUDE-AD trial: targeting soluble amyloid-β oligomers with sabirnetug in AD 1:43
The ALTITUDE-AD trial: targeting soluble amyloid-β oligomers with sabirnetug in AD
Todd Feaster • 29 Oct 2024

Related Videos

Microbiome-brain volume associations in cognitively unimpaired adults enriched for AD risk 6:35
Microbiome-brain volume associations in cognitively unimpaired adults enriched for AD risk
Muhaison Ibrahim • 10 Dec 2025
Gut microbiome as a risk stratification tool and prevention target for neurodegenerative diseases 3:54
Gut microbiome as a risk stratification tool and prevention target for neurodegenerative diseases
Muhaison Ibrahim • 10 Dec 2025
Shingles vaccination is associated with a reduced risk of new dementia diagnoses 4:49
Shingles vaccination is associated with a reduced risk of new dementia diagnoses
Pascal Geldsetzer • 8 Dec 2025
The potential of plasma biomarkers in assessing preclinical Alzheimer’s disease 3:25
The potential of plasma biomarkers in assessing preclinical Alzheimer’s disease
Gemma Salvadó • 12 Dec 2025
The content of VJDementia is intended for healthcare professionals